|
Elotuzumab (also known as HuLuc63) is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.〔 〕 In May 2014, it was granted "Breakthrough Therapy" designation by the FDA. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Elotuzumab」の詳細全文を読む スポンサード リンク
|